



CONFIRMATION

The undersigned, Peter Rupprecht and Guido Lindemberger, as authorized signatories of NOVARTIS AG, a company organized and existing under the laws of Switzerland with main offices at CH - 4002 Basel. Expressly make the following statements:

We hereby confirm that Novartis Pharma AG and Novartis Lateinamerika AG are directly and indirectly a 100 % subsidiary of Novartis AG, Switzerland, as reflected in the consolidated financial statements of the Novartis Group as of December 31 2009, whose financial information has been officially certified by external auditors, and is public through its website www.novartis.com.

On the other hand, I declare that Novartis AG is headquartered in Basel, Switzerland, and is registered with the Commercial Registry of the Canton of Basel under No. CH-270.3.002.061-2 of March 1, 1996.

Appended is page 242 / 31 "Main Group and Associated Companies operating subsidiary" from the Annual Report dated December 31, 2009, duly certified

Date: 23rd February 2011

CONFIRMACION

Nosotros, Peter Rupprecht y Guido Lindemberger, autorizados por NOVARTIS AG, una sociedad organizada y existentes bajo las leyes de Suiza con oficinas principales en CH - 4002 Basilea. En forma expresa lo siguiente:

Confirmamos que Novartis Pharma AG y Novartis Lateinamerika son directamente e indirectamente en un 100% subsidiarias de Novartis AG, Suiza, según se desprende de los Estados Contables Consolidados del Grupo NOVARTIS al 31 de diciembre de 2009, cuya información financiera ha sido oficialmente certificada por los auditores externos, y es de dominio público a través de su página web www.novartis.com.

Por otro lado, declaro que NOVARTIS AG tiene su sede social en Basilea, Suiza, y se encuentra inscripta en el Registro Público de Comercial del Cantón de Basilea, bajo el No. CH-270.3.002.061-2 del 1 de marzo de 1996.

Se anexan la página 242 / 31 "Principal Group Subsidiaries and Associated Companies" del Reporte Anual al 31 de diciembre de 2009, debidamente certificado.

Fecha: 23 de febrero de 2011


Novartis AG

Signed by: /
Firmado por:
Title / Título:

P. Rupprecht

Authorized Signatories both / Personas Autorizadas

G. Lindemberger



PRINCIPAL GROUP SUBSIDIARIES AND ASSOCIATED COMPANIES

December 31, 2009	Share/paid-in capital ¹	Equity Interest %	Activities	As at December 31, 2009	Share/paid-in capital ¹	Equity Interest %	Activities
Argentina				France			
Novartis Argentina S.A., Buenos Aires	ARS 61.3 m	100	◆▲	Novartis Groupe France S.A., Rueil-Malmaison	EUR 103.0 m	100	■
Sandoz S.A., Buenos Aires	ARS 11.8 m	100	◆▼	Novartis Pharma S.A.S., Rueil-Malmaison	EUR 43.4 m	100	◆▼▲
Australia				Sandoz S.A.S., Levallois-Perret	EUR 5.0 m	100	◆
Novartis Australia Pty Ltd., North Ryde, NSW	AUD 11.0 m	100	■	Novartis Santé Familiale S.A.S., Rueil-Malmaison	EUR 21.9 m	100	◆▼
Novartis Pharmaceuticals Australia Pty Ltd., North Ryde, NSW	AUD 3.8 m	100	◆▲	Novartis Santé Animale S.A.S., Rueil-Malmaison	EUR 900 000	100	◆▼
Sandoz Pty Ltd., North Ryde, NSW	AUD 11.6 m	100	◆	CIBA Vision S.A.S., Blagnac	EUR 1.8 m	100	◆
Novartis Consumer Health Australasia Pty Ltd., Melbourne, Victoria	AUD 7.6 m	100	◆▼	Germany			
Novartis Animal Health Australasia Pty Ltd., North Ryde, NSW	AUD 3.0 m	100	◆▲	Novartis Deutschland GmbH, Wehr	EUR 155.5 m	100	■
Austria				Novartis Pharma GmbH, Nuremberg	EUR 25.6 m	100	◆▲
Novartis Austria GmbH, Vienna	EUR 1.0 m	100	■	Novartis Pharma Produktions GmbH, Wehr	EUR 2.0 m	100	▼
Novartis Pharma GmbH, Vienna	EUR 1.1 m	100	◆	Novartis Vaccines and Diagnostics GmbH, Marburg	EUR 5.0 m	100	◆▼▲
Sandoz GmbH, Kundl	EUR 32.7 m	100	◆▼▲	Jenahexal Pharma GmbH, Jena	EUR 260 000	100	◆▼▲
Novartis Animal Health GmbH, Kundl	EUR 37 000	100	◆	Sandoz International GmbH, Holzkirchen	EUR 100 000	100	■
Bangladesh				Sandoz Pharmaceuticals GmbH, Holzkirchen	EUR 5.1 m	100	◆
Novartis (Bangladesh) Limited, Dhaka	BDT 162.5 m	60	◆▼	Sandoz Industrial Products GmbH, Frankfurt a. M.	EUR 2.6 m	100	◆▼
Belgium				Hexal AG, Holzkirchen	EUR 93.7 m	100	◆▼▲
N.V. Novartis Pharma S.A., Vilvoorde	EUR 7.1 m	100	◆	Salutas Pharma GmbH, Barleben	EUR 42.1 m	100	◆▼
N.V. Sandoz S.A., Vilvoorde	EUR 19.2 m	100	◆	1 A Pharma GmbH, Oberhaching	EUR 26 000	100	◆
N.V. Novartis Consumer Health S.A., Vilvoorde	EUR 4.3 m	100	◆	Novartis Consumer Health GmbH, Munich	EUR 14.6 m	100	◆▼▲
N.V. CIBA Vision Benelux S.A., Mechelen	EUR 62 000	100	◆	Novartis Tiergesundheit GmbH, Munich	EUR 256 000	100	◆
Bermuda				CIBA Vision Vertriebs GmbH, Grossostheim	EUR 2.6 m	100	◆
Triangle International Reinsurance Ltd., Hamilton	CHF 1.0 m	100	■	CIBA Vision GmbH, Grosswallstadt	EUR 15.4 m	100	◆▼▲
Novartis Securities Investment Ltd., Hamilton	CHF 30 000	100	■	Gibraltar			
Novartis International Pharmaceutical Ltd., Hamilton	CHF 20.0 m	100	◆▼▲	Novista Insurance Limited, Gibraltar	CHF 130.0 m	100	■
Brazil				Great Britain			
Novartis Biociências S.A., São Paulo	BRL 255.8 m	100	◆▼	Novartis UK Limited, Frimley/Camberley	GBP 25.5 m	100	■
Sandoz do Brasil Indústria Farmacêutica Ltda., Cambé	BRL 189.9 m	100	◆▼▲	Novartis Pharmaceuticals UK Limited, Frimley/Camberley	GBP 5.4 m	100	◆▼▲
Novartis Saúde Animal Ltda., São Paulo	BRL 50.7 m	100	◆▼	Novartis Vaccines and Diagnostics Limited, Frimley/Camberley	GBP 100	100	▼
Canada				Novartis Grimsby Limited, Frimley/Camberley	GBP 230 m	100	▼
Novartis Pharmaceuticals Canada Inc., Dorval/Montreal	CAD 0 ²	100	◆▲	Sandoz Limited, Bordon	GBP 2.0 m	100	◆
Sandoz Canada Inc., Boucherville, Quebec	CAD 76.8 m	100	◆▼▲	Novartis Consumer Health UK Limited, Horsham	GBP 25 000	100	◆▼
Novartis Consumer Health Canada Inc., Mississauga, Ontario	CAD 2	100	◆	Novartis Animal Health UK Limited, Frimley/Camberley	GBP 100 000	100	◆▲
CIBA Vision Canada Inc., Mississauga, Ontario	CAD 1	100	◆▼	CIBA Vision (UK) Limited, Southampton	GBP 550 000	100	◆
Novartis Animal Health Canada Inc., Charlottetown	CAD 2	100	◆▲	Greece			
Chile				Novartis (Hellas) S.A.C.I., Metamorphosis/Athens	EUR 14.6 m	100	◆
Novartis Chile S.A., Santiago de Chile	CLP 2.0 bn	100	◆	Hungary			
China				Novartis Hungary Healthcare Limited Liability Company, Budapest	HUF 545.6 m	100	◆
Beijing Novartis Pharma Co., Ltd., Beijing	CNY 132.1 m	100	◆▼	Sandoz Hungary Limited Liability Company, Budapest	HUF 4.0 m	100	◆
Novartis Pharmaceuticals (HK) Limited, Hong Kong	HKD 200	100	◆	India			
China Novartis Institutes for Biomedical Research Co. Ltd., Shanghai	USD 32.0 m	100	▲	Novartis India Limited, Mumbai	INR 159.8 m	76	◆▼
Suzhou Novartis Pharma Technology Co. Ltd., Changshu	USD 62.0 m	100	▼	Sandoz Private Limited, Mumbai	INR 32.0 m	100	◆▼
Shanghai Novartis Trading Ltd., Shanghai	CNY 20.3 m	100	◆	Indonesia			
Colombia				PT Novartis Indonesia, Jakarta	IDR 7.7 bn	100	◆▼
Novartis de Colombia S.A., Santafé de Bogotá	COP 7.9 bn	100	◆▼	PT CIBA Vision Batam, Batam	IDR 11.9 bn	100	▼
Croatia				Ireland			
lek Zagreb d.o.o., Zagreb	HRK 25.6 m	100	◆	Novartis Ireland Limited, Dublin	EUR 25 000	100	◆
Czech Republic				Novartis Ringaskiddy Limited, Ringaskiddy, County Cork	EUR 2.0 m	100	▼
Novartis s.r.o., Prague	CZK 51.5 m	100	◆	Chiron Healthcare Ireland Limited, Ringaskiddy, County Cork	EUR 2	100	◆
Sandoz s.r.o., Prague	CZK 44.7 m	100	◆	Italy			
Denmark				Novartis Farma S.p.A., Origgio	EUR 18.2 m	100	◆▼▲
Novartis Healthcare A/S, Copenhagen	DKK 14.0 m	100	◆	Novartis Vaccines and Diagnostics S.r.l., Siena	EUR 41.5 m	100	◆▼▲
Sandoz A/S, Copenhagen	DKK 8.0 m	100	◆	Sandoz S.p.A., Origgio	EUR 390 000	100	◆
Ecuador				Sandoz Industrial Products S.p.A., Rovereto	EUR 2.6 m	100	▼
Novartis Ecuador S.A., Quito	USD 4.0 m	100	◆	Novartis Consumer Health S.p.A., Origgio	EUR 2.9 m	100	◆
Egypt				CIBA Vision S.r.l., Marcon	EUR 2.4 m	100	◆
Novartis Pharma S.A.E., Cairo	EGP 33.8 m	99	▼	Japan			
Novartis Egypt (Healthcare) S.A.E., Cairo	EGP 250 000	96	◆	Novartis Holding Japan K.K., Tokyo	JPY 10.0 m	100	■
Finland				Novartis Pharma K.K., Tokyo	JPY 6.0 bn	100	◆▲
Novartis Finland Oy, Espoo	EUR 459 000	100	◆	Sandoz K.K., Tokyo	JPY 100.1 m	100	◆▼▲
				Novartis Animal Health K.K., Tokyo	JPY 50.0 m	100	◆▲
				CIBA Vision K.K., Tokyo	JPY 100.0 m	100	◆
				Luxembourg			
				Novartis Investments S.à r.l., Luxembourg	USD 2.6 bn	100	■
				Novartis Finance S.A., Luxembourg	USD 100 000	100	■

As at December 31, 2009

Share/paid-in
capital¹ Equity
Interest % Activities

Malaysia				
Novartis Corporation (Malaysia) Sdn. Bhd., Kuala Lumpur	MYR 3.3 m	100	◆	
CIBA Vision Johor Sdn. Bhd., Gelang Patah	MYR 5.0 m	100	▼	
Mexico				
Novartis Farmacéutica, S.A. de C.V., Mexico City	MXN 205.0 m	100	◆▼	
Sandoz S.A. de C.V., Mexico City	MXN 468.2 m	100	◆▼	
Netherlands				
Novartis Netherlands B.V., Arnhem	EUR 1.4 m	100	■	
Novartis Pharma B.V., Arnhem	EUR 4.5 m	100	◆	
Sandoz B.V., Almere	EUR 907 570	100	◆▼	
Novartis Consumer Health B.V., Breda	EUR 23 830	100	◆▼	
New Zealand				
Novartis New Zealand Ltd., Auckland	NZD 820 000	100	◆	
Norway				
Novartis Norge AS, Oslo	NOK 1.5 m	100	◆	
Pakistan				
Novartis Pharma (Pakistan) Limited, Karachi	PKR 24.8 m	98	◆▼	
Panama				
Novartis Pharma (Logistics), Inc., Panama	USD 10 000	100	◆	
Philippines				
Novartis Healthcare Philippines, Inc., Makati/Manila	PHP 298.8 m	100	◆	
Poland				
Novartis Poland Sp. z o.o., Warsaw	PLN 44.2 m	100	◆	
Lek S.A., Strykow	PLN 5.7 m	100	◆▼	
Portugal				
Novartis Portugal SGPS Lda., Sintra	EUR 500 000	100	■	
Novartis Farma – Produtos Farmacêuticos S.A., Sintra	EUR 2.4 m	100	◆	
Novartis Consumer Health – Produtos Farmacêuticos e Nutrição Lda., Lisbon	EUR 100 000	100	◆	
Puerto Rico				
Ex-Lax, Inc., Humacao	USD 10 000	100	▼	
CIBA Vision Puerto Rico, Inc., Cidra	USD 1 000	100	▼	
Romania				
Sandoz S.R.L., Targu-Mures	RON 35.2 m	100	◆▼	
Russian Federation				
Novartis Pharma LLC, Moscow	RUR 20.0 m	100	◆	
ZAO Sandoz, Moscow	RUR 57.4 m	100	◆	
Novartis Consumer Health LLC, Moscow	RUR 60.0 m	100	◆	
Singapore				
Novartis Singapore Pharmaceutical Manufacturing Pte Ltd., Singapore	SGD 45.0 m	100	▼	
Novartis Asia Pacific Pharmaceuticals Pte Ltd., Singapore	SGD 1.0 m	100	◆	
Novartis Institute for Tropical Diseases Pte Ltd., Singapore	SGD 2 004	100	▲	
Slovakia				
Novartis Slovakia s.r.o., Bratislava	EUR 2.0 m	100	◆	
Slovenia				
Lek Pharmaceuticals d.d., Ljubljana	EUR 73.6 m	100	■◆▼▲	
Sandoz Pharmaceuticals d.d., Ljubljana	EUR 1.5 m	100	◆	
South Africa				
Novartis South Africa (Pty) Ltd., Kempton Park	ZAR 86.4 m	100	◆	
Sandoz South Africa (Pty) Ltd, Kempton Park	ZAR 3.0 m	100	◆▼	
South Korea				
Novartis Korea Ltd., Seoul	KRW 24.5 bn	99	◆	
Spain				
Novartis Farmacéutica, S.A., Barcelona	EUR 63.0 m	100	■◆▼	
Sandoz Farmacéutica, S.A., Barcelona	EUR 270 450	100	◆	
Bexal Farmacéutica, S.A., Madrid	EUR 1.0 m	100	◆	
Novartis Vaccines and Diagnostics, S.L., Barcelona	EUR 675 450	100	◆	
Sandoz Industrial Products, S.A., Les Franqueses del Vallès/Barcelona	EUR 9.3 m	100	◆▼▲	
Novartis Consumer Health, S.A., Barcelona	EUR 876 919	100	◆	
CIBA Vision, S.A., Barcelona	EUR 1.4 m	100	◆	
Sweden				
Novartis Sverige Participations AB, Täby/Stockholm	SEK 1.0 m	100	■	
Novartis Sverige AB, Täby/Stockholm	SEK 5.0 m	100	◆	
CIBA Vision Nordic AB, Askim/Göteborg	SEK 2.5 m	100	◆	

As at December 31, 2009

Share/paid-in
capital¹ Equity
Interest % Activities

Switzerland				
Novartis International AG, Basel	CHF 10.0 m	100	■	
Novartis Holding AG, Basel	CHF 100.2 m	100	■	
Novartis Research Foundation, Basel	CHF 29.3 m	100	▲	
Novartis Foundation for Management Development, Basel	CHF 100 000	100	■	
Novartis Foundation for Employee Participation, Basel	CHF 100 000	100	■	
Novartis Sanierungsstiftung, Basel	CHF 2.0 m	100	■	
Roche Holding AG, Basel	CHF 160.0 m	33/6 ³	■◆▼▲	
Alcon, Inc., Hünenberg	CHF 14.8 m	25	■	
Novartis Pharma AG, Basel	CHF 350.0 m	100	■◆▼▲	
Novartis Pharma Services AG, Basel	CHF 20.0 m	100	◆	
Novartis Pharma Schweizerhalle AG, Muttentz	CHF 18.9 m	100	▼	
Novartis Pharma Stein AG, Stein	CHF 251 000	100	▼▲	
Novartis Pharma Schweiz AG, Bern	CHF 5.0 m	100	◆	
Speedel Holding AG, Basel	CHF 15.8 m	100	■	
Sandoz AG, Basel	CHF 5.0 m	100	◆▲	
Sandoz Pharmaceuticals AG, Steinhausen	CHF 100 000	100	◆	
Novartis Consumer Health S.A., Nyon	CHF 30.0 m	100	■◆▼▲	
Novartis Consumer Health Schweiz AG, Bern	CHF 250 000	100	◆	
Novartis Animal Health AG, Basel	CHF 101 000	100	■◆▼▲	
Novartis Centre de Recherche Santé Animale S.A., St. Aubin	CHF 250 000	100	▲	
CIBA Vision AG, Embrach	CHF 300 000	100	■◆	
Taiwan				
Novartis (Taiwan) Co., Ltd., Taipei	TWD 170.0 m	100	◆▼	
Thailand				
Novartis (Thailand) Limited, Bangkok	THB 230.0 m	100	◆	
Turkey				
Novartis Sağlık, Gıda ve Tarım Ürünleri Sanayi ve Ticaret A.Ş., Istanbul	TRY 98.0 m	100	◆▼	
Sandoz İlaç Sanayi ve Ticaret A.Ş., Kadıköy-Istanbul	TRY 31.7 m	100	◆▼	
USA				
Novartis Corporation, East Hanover, NJ	USD 72.2 m	100	■	
Novartis Finance Corporation, New York, NY	USD 1.7 bn	100	■	
Novartis Capital Corporation, New York, NY	USD 1	100	■	
Novartis Pharmaceuticals Corporation, East Hanover, NJ	USD 5.2 m	100	◆▼▲	
Novartis Institutes for BioMedical Research, Inc., Cambridge, MA	USD 1	100	▲	
Novartis Institute for Functional Genomics, Inc., San Diego, CA	USD 21 000	100	▲	
Idenix Pharmaceuticals, Inc., Cambridge, MA	USD 59 019	47	▲	
Novartis Vaccines and Diagnostics, Inc., Cambridge, MA	USD 3.0	100	■◆▼▲	
Sandoz Inc., Princeton, NJ	USD 25 000	100	◆▼▲	
Eon Labs, Inc., Princeton, NJ	USD 1	100	◆▼	
Novartis Consumer Health, Inc., Parsippany, NJ	USD 0 ²	100	◆▼▲	
Novartis Animal Health US, Inc., Greensboro, NC	USD 100	100	◆▼▲	
CIBA Vision Corporation, Duluth, GA	USD 301.3 m	100	■◆▼▲	
Venezuela				
Novartis de Venezuela, S.A., Caracas	VEB 1.4 bn	100	◆	

In addition, the Group is represented by subsidiaries, associated companies or joint ventures in the following countries: Algeria, Cayman Islands, Costa Rica, Dominican Republic, Guatemala, the former Yugoslav Republic of Macedonia, Morocco, Peru and Uruguay.

Equity interest % – above 50% and up to 100% of the voting rights – fully consolidated
– above 20% and up to 50% of the voting rights – investment in associated company – equity method accounting

¹Share/paid-in capital may not reflect the taxable share/paid-in capital amount and does not include any paid-in surplus.

²shares without par value

³Percentage of total net income and equity attributable to Novartis
m = million; bn = billion

The following describe the various types of entities within the Group:

■ **Holding/Finance:** This entity is a holding company and/or performs finance functions for the Group.

◆ **Sales:** This entity performs sales and marketing activities for the Group.

▼ **Production:** This entity performs manufacturing and/or production activities for the Group.

▲ **Research:** This entity performs research and development activities for the Group.

31. PRINCIPAL GROUP SUBSIDIARIES AND ASSOCIATED COMPANIES

As at December 31, 2009	Share/paid-in capital ¹	Equity Interest %	Activities	As at December 31, 2009	Share/paid-in capital ¹	Equity Interest %	Activities
Argentina				France			
Novartis Argentina S.A., Buenos Aires	ARS 61.3 m	100	◆▲	Novartis Groupe France S.A., Rueil-Malmaison	EUR 103.0 m	100	■
Sandoz S.A., Buenos Aires	ARS 11.8 m	100	◆▼	Novartis Pharma S.A.S., Rueil-Malmaison	EUR 43.4 m	100	◆▼▲
Australia				Sandoz S.A.S., Levallois-Perret	EUR 5.0 m	100	◆
Novartis Australia Pty Ltd., North Ryde, NSW	AUD 11.0 m	100	■	Novartis Santé Familiale S.A.S., Rueil-Malmaison	EUR 21.9 m	100	◆▼
Novartis Pharmaceuticals Australia Pty Ltd., North Ryde, NSW	AUD 3.8 m	100	◆▲	Novartis Santé Animale S.A.S., Rueil-Malmaison	EUR 900 000	100	◆▼
Sandoz Pty Ltd., North Ryde, NSW	AUD 11.6 m	100	◆	CIBA Vision S.A.S., Blagnac	EUR 1.8 m	100	◆
Novartis Consumer Health Australasia Pty Ltd., Melbourne, Victoria	AUD 7.6 m	100	◆▼	Germany			
Novartis Animal Health Australasia Pty Ltd., North Ryde, NSW	AUD 3.0 m	100	◆▲	Novartis Deutschland GmbH, Wehr	EUR 155.5 m	100	■
Austria				Novartis Pharma GmbH, Nuremberg	EUR 25.6 m	100	◆▲
Novartis Austria GmbH, Vienna	EUR 1.0 m	100	■	Novartis Pharma Produktions GmbH, Wehr	EUR 2.0 m	100	▼
Novartis Pharma GmbH, Vienna	EUR 1.1 m	100	◆	Novartis Vaccines and Diagnostics GmbH, Marburg	EUR 5.0 m	100	◆▼▲
Sandoz GmbH, Kundl	EUR 32.7 m	100	◆▼▲	Jenahexal Pharma GmbH, Jena	EUR 260 000	100	◆▼▲
Novartis Animal Health GmbH, Kundl	EUR 37 000	100	◆	Sandoz International GmbH, Holzkirchen	EUR 100 000	100	■
Bangladesh				Sandoz Pharmaceuticals GmbH, Holzkirchen	EUR 5.1 m	100	◆
Novartis (Bangladesh) Limited, Dhaka	BDT 162.5 m	60	◆▼	Sandoz Industrial Products GmbH, Frankfurt a. M.	EUR 2.6 m	100	◆▼
Belgium				Hexal AG, Holzkirchen	EUR 93.7 m	100	◆▼▲
J.V. Novartis Pharma S.A., Vilvoorde	EUR 7.1 m	100	◆	Salutas Pharma GmbH, Barleben	EUR 42.1 m	100	◆▼
J.V. Sandoz S.A., Vilvoorde	EUR 19.2 m	100	◆	1 A Pharma GmbH, Oberhaching	EUR 26 000	100	◆
J.V. Novartis Consumer Health S.A., Vilvoorde	EUR 4.3 m	100	◆	Novartis Consumer Health GmbH, Munich	EUR 14.6 m	100	◆▼▲
J.V. CIBA Vision Benelux S.A., Mechelen	EUR 62 000	100	◆	Novartis Tiergesundheit GmbH, Munich	EUR 256 000	100	◆
Bermuda				CIBA Vision Vertriebs GmbH, Grossostheim	EUR 2.6 m	100	◆
Triangle International Reinsurance Ltd., Hamilton	CHF 1.0 m	100	■	CIBA Vision GmbH, Grosswallstadt	EUR 15.4 m	100	◆▼▲
Novartis Securities Investment Ltd., Hamilton	CHF 30 000	100	■	Gibraltar			
Novartis International Pharmaceutical Ltd., Hamilton	CHF 20.0 m	100	◆▼▲	Novista Insurance Limited, Gibraltar	CHF 130.0 m	100	■
Brazil				Great Britain			
Novartis Biocências S.A., São Paulo	BRL 255.8 m	100	◆▼	Novartis UK Limited, Frimley/Camberley	GBP 25.5 m	100	■
Sandoz do Brasil Indústria Farmacêutica Ltda., Cambé	BRL 189.9 m	100	◆▼▲	Novartis Pharmaceuticals UK Limited, Frimley/Camberley	GBP 5.4 m	100	◆▼▲
Novartis Saúde Animal Ltda., São Paulo	BRL 50.7 m	100	◆▼	Novartis Vaccines and Diagnostics Limited, Frimley/Camberley	GBP 100	100	▼
Canada				Novartis Grimsby Limited, Frimley/Camberley	GBP 230 m	100	▼
Novartis Pharmaceuticals Canada Inc., Dorval/Montreal	CAD 0 ²	100	◆▲	Sandoz Limited, Bordon	GBP 2.0 m	100	◆
Sandoz Canada Inc., Boucherville, Quebec	CAD 76.8 m	100	◆▼▲	Novartis Consumer Health UK Limited, Horsham	GBP 25 000	100	◆▼
Novartis Consumer Health Canada Inc., Mississauga, Ontario	CAD 2	100	◆	Novartis Animal Health UK Limited, Frimley/Camberley	GBP 100 000	100	◆▲
A Vision Canada Inc., Mississauga, Ontario	CAD 1	100	◆▼	CIBA Vision (UK) Limited, Southampton	GBP 550 000	100	◆
Novartis Animal Health Canada Inc., Chariottetown	CAD 2	100	◆▲	Greece			
Chile				Novartis (Hellas) S.A.C.I., Metamorphosis/Athens	EUR 14.6 m	100	◆
Novartis Chile S.A., Santiago de Chile	CLP 2.0 bn	100	◆	Hungary			
China				Novartis Hungary Healthcare Limited Liability Company, Budapest	HUF 545.6 m	100	◆
Sino Novartis Pharma Co., Ltd., Beijing	CNY 132.1 m	100	◆▼	Sandoz Hungary Limited Liability Company, Budapest	HUF 4.0 m	100	◆
Novartis Pharmaceuticals (HK) Limited, Hong Kong	HKD 200	100	◆	India			
Novartis Institutes for BioMedical Research Inc., Shanghai	USD 32.0 m	100	▲	Novartis India Limited, Mumbai	INR 159.8 m	76	◆▼
Sino Novartis Pharma Technology Co. Ltd., Shanghai	USD 62.0 m	100	▼	Sandoz Private Limited, Mumbai	INR 32.0 m	100	◆▼
Shanghai Novartis Trading Ltd., Shanghai	CNY 20.3 m	100	◆	Indonesia			
Colombia				PT Novartis Indonesia, Jakarta	IDR 7.7 bn	100	◆▼
Novartis de Colombia S.A., Santa Fé de Bogotá	COP 7.9 bn	100	◆▼	PT CIBA Vision Batam, Batam	IDR 11.9 bn	100	▼
Croatia				Ireland			
Novartis d.o.o., Zagreb	HRK 25.6 m	100	◆	Novartis Ireland Limited, Dublin	EUR 25 000	100	◆
Czech Republic				Novartis Ringaskiddy Limited, Ringaskiddy, County Cork	EUR 2.0 m	100	▼
Novartis s.r.o., Prague	CZK 51.5 m	100	◆	Chiron Healthcare Ireland Limited, Ringaskiddy, County Cork	EUR 2	100	◆
Novartis s.r.o., Prague	CZK 44.7 m	100	◆	Italy			
Denmark				Novartis Farma S.p.A., Origgio	EUR 18.2 m	100	◆▼▲
Novartis Healthcare A/S, Copenhagen	DKK 14.0 m	100	◆	Novartis Vaccines and Diagnostics S.r.l., Siena	EUR 41.5 m	100	◆▼▲
Novartis A/S, Copenhagen	DKK 8.0 m	100	◆	Sandoz S.p.A., Origgio	EUR 390 000	100	◆
Ecuador				Sandoz Industrial Products S.p.A., Rovereto	EUR 2.6 m	100	▼
Novartis Ecuador S.A., Quito	USD 4.0 m	100	◆	Novartis Consumer Health S.p.A., Origgio	EUR 2.9 m	100	▼
Egypt				CIBA Vision S.r.l., Marcon	EUR 2.4 m	100	◆
Novartis Pharma S.A.E., Cairo	EGP 33.8 m	99	▼	Japan			
Novartis Egypt (Healthcare) S.A.E., Cairo	EGP 250 000	96	◆	Novartis Holding Japan K.K., Tokyo	JPY 10.0 m	100	■
Finland				Novartis Pharma K.K., Tokyo	JPY 6.0 bn	100	◆▲
Novartis Oy, Espoo	EUR 459 000	100	◆	Sandoz K.K., Tokyo	JPY 100.1 m	100	◆▼▲
				Novartis Animal Health K.K., Tokyo	JPY 50.0 m	100	◆▲
				CIBA Vision K.K., Tokyo	JPY 100.0 m	100	◆
				Luxembourg			
				Novartis Investments S.A. r.l., Luxembourg	USD 2.6 bn	100	■
				Novartis Finance S.A., Luxembourg	USD 100 000	100	■

As at December 31, 2009	Share/paid-in capital ¹	Equity interest %	Activities	As at December 31, 2009	Share/paid-in capital ¹	Equity interest %	Activities
Malaysia				Switzerland			
Novartis Corporation (Malaysia) Sdn. Bhd., Kuala Lumpur	MYR 3.3 m	100	+	Novartis International AG, Basel	CHF 10.0 m	100	■
CIBA Vision Johor Sdn. Bhd., Gelang Patah	MYR 5.0 m	100	▼	Novartis Holding AG, Basel	CHF 100.2 m	100	■
Mexico				Novartis Research Foundation, Basel	CHF 29.3 m	100	▲
Novartis Farmacéutica, S.A. de C.V., Mexico City	MXN 205.0 m	100	◆▼	Novartis Foundation for Management Development, Basel	CHF 100 000	100	■
Sandoz S.A. de C.V., Mexico City	MXN 468.2 m	100	◆▼	Novartis Foundation for Employee Participation, Basel	CHF 100 000	100	■
Netherlands				Novartis Sanierungsstiftung, Basel	CHF 2.0 m	100	■
Novartis Netherlands B.V., Arnhem	EUR 1.4 m	100	■	Roche Holding AG, Basel	CHF 160.0 m	33/6 ³	■◆▼▲
Novartis Pharma B.V., Arnhem	EUR 4.5 m	100	◆	Alcon, Inc., Hünenberg	CHF 14.8 m	25	■
Sandoz B.V., Almere	EUR 907 570	100	◆▼	Novartis Pharma AG, Basel	CHF 350.0 m	100	■◆▼▲
Novartis Consumer Health B.V., Breda	EUR 23 830	100	◆▼	Novartis Pharma Services AG, Basel	CHF 20.0 m	100	◆
New Zealand				Novartis Pharma Schweizerhalle AG, Muttentz	CHF 18.9 m	100	▼
Novartis New Zealand Ltd., Auckland	NZD 820 000	100	◆	Novartis Pharma Stein AG, Stein	CHF 251 000	100	▼▲
Norway				Novartis Pharma Schweiz AG, Bern	CHF 5.0 m	100	◆
Novartis Norge AS, Oslo	NOK 1.5 m	100	◆	Speedel Holding AG, Basel	CHF 15.8 m	100	■
Pakistan				Sandoz AG, Basel	CHF 5.0 m	100	◆▲
Novartis Pharma (Pakistan) Limited, Karachi	PKR 24.8 m	98	◆▼	Sandoz Pharmaceuticals AG, Steinhausen	CHF 100 000	100	◆
Panama				Novartis Consumer Health S.A., Nyon	CHF 30.0 m	100	■◆▼▲
Novartis Pharma (Logistics), Inc., Panama	USD 10 000	100	+	Novartis Consumer Health Schweiz AG, Bern	CHF 250 000	100	◆
Philippines				Novartis Animal Health AG, Basel	CHF 101 000	100	■◆▼▲
Novartis Healthcare Philippines, Inc., Makati/Manila	PHP 298.8 m	100	◆	Novartis Centre de Recherche Santé Animale S.A., St. Aubin	CHF 250 000	100	▲
Poland				CIBA Vision AG, Embrach	CHF 300 000	100	■◆
Novartis Poland Sp. z o.o., Warsaw	PLN 44.2 m	100	◆	Taiwan			
Lek S.A., Strykow	PLN 5.7 m	100	◆▼	Novartis (Taiwan) Co., Ltd., Taipei	TWD 170.0 m	100	◆▼
Portugal				Thailand			
Novartis Portugal SGPS Lda., Sintra	EUR 500 000	100	■	Novartis (Thailand) Limited, Bangkok	THB 230.0 m	100	◆
Novartis Farma – Produtos Farmacêuticos S.A., Sintra	EUR 2.4 m	100	◆	Turkey			
Novartis Consumer Health – Produtos Farmacêuticos e Nutrição Lda., Lisbon	EUR 100 000	100	+	Novartis Sağlık, Gıda ve Tarım Ürünleri Sanayi ve Ticaret A.Ş., Istanbul	TRY 98.0 m	100	◆▼
Puerto Rico				Sandoz İlaç Sanayi ve Ticaret A.Ş., Kadıköy-Istanbul	TRY 31.7 m	100	◆▼
Ex-Lax, Inc., Humacao	USD 10 000	100	▼	USA			
CIBA Vision Puerto Rico, Inc., Cidra	USD 1 000	100	▼	Novartis Corporation, East Hanover, NJ	USD 72.2 m	100	■
Romania				Novartis Finance Corporation, New York, NY	USD 1.7 bn	100	■
Sandoz S.R.L., Targu-Mures	RON 35.2 m	100	◆▼	Novartis Capital Corporation, New York, NY	USD 1	100	■
Russian Federation				Novartis Pharmaceuticals Corporation, East Hanover, NJ	USD 5.2 m	100	◆▼▲
Novartis Pharma LLC, Moscow	RUR 20.0 m	100	◆	Novartis Institutes for BioMedical Research, Inc., Cambridge, MA	USD 1	100	▲
ZAO Sandoz, Moscow	RUR 57.4 m	100	◆	Novartis Institute for Functional Genomics, Inc., San Diego, CA	USD 21 000	100	▲
Novartis Consumer Health LLC, Moscow	RUR 60.0 m	100	◆	Idenix Pharmaceuticals, Inc., Cambridge, MA	USD 59 019	47	▲
Singapore				Novartis Vaccines and Diagnostics, Inc., Cambridge, MA	USD 3.0	100	■◆▼▲
Novartis Singapore Pharmaceutical Manufacturing Pte Ltd., Singapore	SGD 45.0 m	100	▼	Sandoz Inc., Princeton, NJ	USD 25 000	100	◆▼▲
Novartis Asia Pacific Pharmaceuticals Pte Ltd., Singapore	SGD 1.0 m	100	◆	Eon Labs, Inc., Princeton, NJ	USD 1	100	◆▼
Novartis Institute for Tropical Diseases Pte Ltd., Singapore	SGD 2 004	100	▲	Novartis Consumer Health, Inc., Parsippany, NJ	USD 0 ²	100	◆▼▲
Slovakia				Novartis Animal Health US, Inc., Greensboro, NC	USD 100	100	◆▼▲
Novartis Slovakia s.r.o., Bratislava	EUR 2.0 m	100	◆	CIBA Vision Corporation, Duluth, GA	USD 301.3 m	100	■◆▼▲
Slovenia				Venezuela			
Lek Pharmaceuticals d.d., Ljubljana	EUR 73.6 m	100	■◆▼▲	Novartis de Venezuela, S.A., Caracas	VEB 1.4 bn	100	◆
Sandoz Pharmaceuticals d.d., Ljubljana	EUR 1.5 m	100	◆				
South Africa							
Novartis South Africa (Pty) Ltd., Kempton Park	ZAR 86.4 m	100	◆				
Sandoz South Africa (Pty) Ltd, Kempton Park	ZAR 3.0 m	100	◆▼				
South Korea							
Novartis Korea Ltd., Seoul	KRW 24.5 bn	99	◆				
Spain							
Novartis Farmacéutica, S.A., Barcelona	EUR 63.0 m	100	■◆▼				
Sandoz Farmacéutica, S.A., Barcelona	EUR 270 450	100	◆				
Bexal Farmacéutica, S.A., Madrid	EUR 1.0 m	100	◆				
Novartis Vaccines and Diagnostics, S.L., Barcelona	EUR 675 450	100	◆				
Sandoz Industrial Products, S.A., Les Franqueses del Vallés/Barcelona	EUR 9.3 m	100	◆▼▲				
Novartis Consumer Health, S.A., Barcelona	EUR 876 919	100	◆				
CIBA Vision, S.A., Barcelona	EUR 1.4 m	100	+				
Sweden							
Novartis Sverige Participations AB, Täby/Stockholm	SEK 1.0 m	100	■				
Novartis Sverige AB, Täby/Stockholm	SEK 5.0 m	100	+				
CIBA Vision Nordic AB, Askim/Göteborg	SEK 2.5 m	100	+				

In addition, the Group is represented by subsidiaries, associated companies or joint ventures in the following countries: Algeria, Cayman Islands, Costa Rica, Dominican Republic, Guatemala, the former Yugoslav Republic of Macedonia, Morocco, Peru and Uruguay.

Equity interest % – above 50% and up to 100% of the voting rights – fully consolidated
– above 20% and up to 50% of the voting rights – investment in associated company – equity method accounting

¹ Share/paid-in capital may not reflect the taxable share/paid-in capital amount and does not include any paid-in surplus.

² Shares without par value

³ Percentage of total net income and equity attributable to Novartis

m = million; bn = billion

The following describe the various types of entities within the Group:

■ Holding/Finance: This entity is a holding company and/or performs finance functions for the Group.

◆ Sales: This entity performs sales and marketing activities for the Group.

▼ Production: This entity performs manufacturing and/or production activities for the Group.

▲ Research: This entity performs research and development activities for the Group.

ATTESTATION

I, the undersigned Civil Law Notary in Basel, Switzerland, Dr. Matthias Staehelin, certify herewith that the signatures attached heretofore are the genuine signatures of **Mr. Peter Rupprecht**, citizen of Basel, Switzerland, residing in Aesch/BL, Switzerland; and of **Mr. Guido Lindenberger**, citizen of Fehren, Switzerland, residing in Emmetten, Switzerland; both acting for **Novartis AG**, in Basel, Switzerland, both as authorized signatories, both with joint signature.

The authenticity of the signatures was established by means of comparison.

BASEL, Switzerland, this 2nd (second) day of March 2011 (two thousand and eleven)

M. Staehelin, Notar

Dr. M. Staehelin
Notar

Leg.Prot.Nr. 790/2011

APOSTILLE

(Hague Convention of October 5th, 1961)

1. Country: Switzerland (Schweiz/Suisse)
This official document
2. is signed by *Dr. iur. M. Staehelin*
3. in his/her function as *notary public*
4. and certified by the seal of the *above mentioned*


Certified

5. in Basel (Bâle)
6. on *2. März 2011*
7. by the State Chancery of the Canton of Basel-Stadt
8. no. *1297/2909*
9. Seal/stamp:

10. Signature:

Hanna Leuener

Hanna Leuener



POWER-OF-ATTORNEY

Novartis Lateinamerika AG (the "Company"), an entity organized and existing under the laws of Switzerland, with main offices at Lichtstrasse 35, CH-4056 Basel, Switzerland, hereby grants a sufficient power-of-attorney, as required by law, limited to the powers granted to the CPO Head, in favor of Diego Ruiz so that he, on the Company's behalf and in its representation, may answer complaints and fulfill obligations relating to the Company's capacity as a shareholder of Novartis Ecuador S.A. incorporated under the laws of the Republic of Ecuador, as determined under article 6 of the Law on Companies of Ecuador. This Power of Attorney shall be valid for a period of four (4) years, it shall expire therefore on February 17, 2018, unless extended prior to its expiration.

Given and signed in:
Basel / Switzerland, February 17, 2014


(All powers-of-attorney must be executed before a notary public and apostilled or authenticated by the Consul of Ecuador at the company's domicile)

Novartis Lateinamerika AG

(signature/firma)

By/Por:

Occupation/Cargo:


Peter Rupperecht


Apoderado

PODER


Novartis Lateinamerika AG (la "Compañía"), una sociedad organizada y existente bajo las leyes de Suiza, con domicilio principal en Lichtstrasse 35, CH-4056 Basilea, Suiza, por este instrumento otorga poder suficiente cual en derecho se requiere, y solo a favor del Presidente Ejecutivo de Novartis Ecuador S.A. señor Diego Ruiz para que en su nombre y representación, pueda contestar demandas y cumplir las obligaciones contraídas por la Compañía en su calidad de socia o accionista de Novartis Ecuador S.A.; sociedad constituida bajo las leyes de la República del Ecuador de acuerdo a lo dispuesto en el artículo 6 de la Ley de Compañías de Ecuador. Este Poder es valido por un período de cuatro (4) años, por lo tanto expira el 17 de Febrero del 2018, a menos que esta fecha se extienda previa a su expiración.

Dado y firmado en:
Basilea / Suiza, 17 de febrero de 2014

(Todo poder debe ser otorgado ante Notario y apostillado o autenticado por el Cónsul del Ecuador del lugar del domicilio de la compañía)


Luca Mighali

Apoderado




Legalisation

The undersigned Notary Public of the Canton of Basel-City (Switzerland) herewith legalises the signature of the company **Novartis Lateinamerika AG**, in Basel (CHE-102.750.006), Canton of Basel-City (Switzerland), affixed by Mr. Peter Rupprecht, citizen of Basel, domiciled in Aesch, Canton of Basel-Country (Switzerland), secretary of the board of directors (non-member), and Mr. Luca Salvatore Mighali, Italian citizen, domiciled in Arisdorf, Canton of Basel-Country (Switzerland), both persons having joint signatory power at two, the signers and their signatures personally known.

Basel, 18 February 2014.

BR 2014/160



Dr. B. Bessenich
Notar



APOSTILLE

(Convention de la Haye du 5 octobre 1961)

1. Country Land **Swiss Confederation, Canton of Basel-City**
Schweizerische Eidgenossenschaft, Kanton Basel-Stadt

This public document
Diese öffentliche Urkunde

2. has been signed by **Dr.iur. Balthasar Bessenich**
ist unterschrieben von

3. acting in the capacity of **notary public**
in seiner Eigenschaft als

4. bears the stamp/seal of **Bessenich Balthasar**
Sie ist versehen mit dem
Stempel/Siegel des/der


Certified / Bestätigt

5. at / in **Basel** 6. the / am **18.02.2014**

7. by the **Legalisation Office of the Canton of Basel-City**
durch das **Beglaubigungsbüro des Kantons Basel-Stadt**

8. No. / Nr. **22922** tax / Taxe **CHF 20.00**

9. stamp/seal **10. Signature **Hanna Lauener****
Stempel/Siegel Unterschrift



POWER-OF-ATTORNEY

Novartis Pharma AG (the "Company"), an entity organized and existing under the laws of Switzerland, with main offices at Lichtstrasse 35, CH-4056 Basel, Switzerland, hereby grants a sufficient power-of-attorney, as required by law, limited to the powers granted to the CPO Head, in favor of Diego Ruiz so that he, on the Company's behalf and in its representation, may answer complaints and fulfill obligations relating to the Company's capacity as a shareholder of Novartis Ecuador S.A. incorporated under the laws of the Republic of Ecuador, as determined under article 6 of the Law on Companies of Ecuador. This Power of Attorney shall be valid for a period of four (4) years, it shall expire therefore on February 17, 2018, unless extended prior to its expiration.

Given and signed in:
Basel / Switzerland, February 17, 2014


(All powers-of-attorney must be executed before a notary public and apostilled or authenticated by the Consul of Ecuador at the company's domicile)

Novartis Pharma AG

(signature/firma)

By/For:

Occupation/Cargo:


Peter Rupperecht
Apoderado


PODER

Novartis Pharma AG (la "Compañía"), una sociedad organizada y existente bajo las leyes de Suiza, con domicilio principal en Lichtstrasse 35, CH-4056 Basilea, Suiza, por este instrumento otorga poder suficiente cual en derecho se requiere, y solo a favor del Presidente Ejecutivo de Novartis Ecuador S.A. señor Diego Ruiz para que en su nombre y representación, pueda contestar demandas y cumplir las obligaciones contraídas por la Compañía en su calidad de socia o accionista de Novartis Ecuador S.A.; sociedad constituida bajo las leyes de la República del Ecuador de acuerdo a lo dispuesto en el artículo 6 de la Ley de Compañías de Ecuador. Este Poder es valido por un período de cuatro (4) años, por lo tanto expira el 17 de Febrero del 2018, a menos que esta fecha se extienda previa a su expiración

Dado y firmado en:
Basilea / Suiza, 17 de febrero de 2014

(Todo poder debe ser otorgado ante Notario y apostillado o autenticado por el Cónsul del Ecuador del lugar del domicilio de la compañía)


Luca Mighali
Apoderado




Legalisation

The undersigned Notary Public of the Canton of Basel-City (Switzerland) Dr. Balthasar Bessenich herewith legalises the signature of the company **Novartis Pharma AG**, in Basel (CHE-106.052.527), Canton of Basel-City (Switzerland), affixed by Mr. Peter Rupprecht, citizen of Basel, domiciled in Aesch, Canton of Basel-Country (Switzerland), and Mr. Luca Salvatore Mighali, Italian citizen, domiciled in Arisdorf, Canton of Basel-Country (Switzerland), both persons having joint signatory power at two, the signers and their signatures personally known.

Basel, 18 February 2014.

BR 2014/163



NOTARÍA TRIGÉSIMA DE QUITO **Dr. B. Bessenich**
Notar

De acuerdo al Numeral 5 del Art. 18 de la ley Notarial, doy fe
que las copias que antecede son iguales a los documentos
presentados ante mí en 5 foja(s)
Quito a, 19 FEB 2015


Dr. Darío Andrade Arellano.
NOTARIO



APOSTILLE

(Convention de la Haye du 5 octobre 1961)

1. Country Land **Swiss Confederation, Canton of Basel-City**
Schweizerische Eidgenossenschaft, Kanton Basel-Stadt

This public document
Diese öffentliche Urkunde

2. has been signed by **Dr. iur. Balthasar Bessenich**
ist unterschrieben von

3. acting in the capacity of **notary public**
in seiner Eigenschaft als

4. bears the stamp/seal of **Bessenich Balthasar**
Sie ist versehen mit dem
Stempel/Siegel des/der

Certified / Bestätigt

5. at / in **Basel** 6. the / am **18.02.2014**

7. by the **Legalisation Office of the Canton of Basel-City**
durch das **Beglaubigungsbüro des Kantons Basel-Stadt**

8. No. / Nr. **22925** tax / Taxe **CHF 20.00**

stamp/seal
Stempel/Siegel

10. Signature **Hanna Lauener**
Unterschrift





Factura: 002-002-000000278



20151701030D00132

DOCUMENTO EXHIBIDOS N° 20151701030D00132

RAZÓN: De conformidad al Art. 18 numeral 5 de la Ley Notarial, doy fe que el(los) documento(s) que antecede(n) es(son) **igual(es) al(los) documento(s) que me fue(ron) exhibido(s)** en 5 foja(s) útil(es). Una vez practicada la certificación(es) se devuelve el(los) documento(s) en 5 foja(s), conservando una copia de ellas en el Libro de Diligencias. La veracidad de su contenido y el uso adecuado del(los) documento(s) certificado(s) es de responsabilidad exclusiva de la(s) persona(s) que lo(s) utiliza(n).

QUITO, a 19 DE FEBRERO DEL 2015.

NOTARIO(A) DARIO LENIN ANDRADE ARELLANO
NOTARÍA TRIGÉSIMA DEL CANTON QUITO

